Skip to content

Research on the therapeutic effect of Anxin Formula on coronary heart disease patients after stent implantation based on "dual heart homology"

Research on the therapeutic effect of Anxin Formula on coronary heart disease patients after stent implantation based on "dual heart homology"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082401
Enrollment
Unknown
Registered
2024-03-28
Start date
2024-04-01
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

After coronary heart disease stent implantation surgery

Interventions

Treatment group:Anxin Fang
Control group:Anxin Fang placebo

Sponsors

Xiyuan Hospital of Chinese Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) After more than 1 year of percutaneous coronary stent implantation and conventional Western medicine treatment; (2) Traditional Chinese medicine syndrome differentiation is characterized by Qi deficiency and blood stasis combined with liver depression; (3) Patients with mild/moderate anxiety and/or depression have a Hamilton Anxiety Scale score of 7-29 (excluding 29) or a Hamilton Depression Scale score of 7-24 (excluding 24); (4) 35 = Age = 80 years old, gender unlimited; (5) Cardiac function classification = NYHA level II; (6) Sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Have a history of stroke within the past 6 months (cerebral hemorrhage, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism, and stroke attacks of unknown classification); (2) Poorly controlled hypertension (= 180/100mmHg) or hypotension (<90/60mmHg); (3) Recently, there have been repeated occurrences of malignant arrhythmias (ventricular tachycardia, rapid atrial fibrillation, atrial flutter, type II or above atrioventricular block, complete bundle branch block); (4) Concomitant severe liver and kidney dysfunction, other serious primary diseases that affect lifespan, tumors, or psychiatric disorders; (5) Patients with severe anxiety/depression; (6) Patients who have taken anti anxiety and depression drugs within the past 4 weeks; (7) Pregnant, planned pregnancy within the past 3 months, or lactating women; (8) Participants in other clinical trials; (9) Individuals who are allergic to experimental drugs and their components; (10) Current or past history of drug abuse or alcohol dependence or drug use; (11) Unable to understand or refuse to sign informed consent; (12) Other situations where the researcher deems it inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
Seattle angina questionnaire;Hamilton Depression Scale;Hamilton Anxiety Scale;Traditional Chinese Medicine Syndrome Scale;

Secondary

MeasureTime frame
Electrocardiogram;

Countries

China

Contacts

Public ContactGuo Mingdong

Xiyuan Hospital of Chinese Academy of Traditional Chinese Medicine

drgmd@163.com+86 135 2259 3616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026